Candel Therapeutics, Inc. CADL Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s financing cash flow?
- Candel Therapeutics, Inc. (CADL) reported financing cash flow of $93.82M in Q1 2026.
- How has Candel Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Candel Therapeutics, Inc.'s financing cash flow increased by 5116.8% year-over-year, from -$1.87M to $93.82M.
- What is the long-term trend for Candel Therapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s financing cash flow has grown at a -4.6% compound annual growth rate (CAGR), from $71.8M to $59.47M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.